Benzoic acid salt of otamixaban
View Patent ↗The invention relates to a benzoic acid salt of methyl(2R,3R)-2-{3-[amino(imino)methyl]benzyl}-3-{[4-(1-oxidopyridin-4-yl)benzoyl]amino}butanoate, and to a benzoic acid salt of methyl(2R,3R)-2-{3-[amino(imino)methyl]benzyl}-3-{[4-(1-oxidopyridin-4-yl)benzoyl]amino}butanoate which is in a crystalline form or in at least partially crystalline form, as well as a process for the preparation of the same, methods of using such salt to treat subjects suffering from conditions which can be ameliorated by the administration of an inhibitor of Factor Xa.
1. Benzoic acid salt of methyl(2R,3R)-2-{3-[amino(imino)methyl]benzyl}-3-{[4-(1-oxidopyridin-4-yl)benzoyl]amino}butanoate.
2. Benzoic acid salt according to claim 1 which is in a crystalline form or in at least partially crystalline form.
3. Benzoic acid salt according to claim 2 wherein the crystalline salt exhibits in an X-ray powder diffraction pattern measured in transmission with CuKα 1 radiation at room temperature a characteristic reflection at degrees 2 theta of 19.8, 18.8 and 17.9, each time±0.2 degrees 2 theta.
4. Benzoic acid salt according to claim 2 wherein the crystalline salt exhibits in an X-ray powder diffraction pattern measured in transmission with CuKα 1 radiation at room temperature a characteristic reflection at degrees 2 theta of 22.0, 19.8, 18.8, 17.9, 15.7 and 13.6 each time±0.2 degrees 2 theta.
5. Benzoic acid salt according to claim 2 , which is characterized by an x-ray powder diffraction pattern substantially in accordance with that shown in FIG. 1 .
6. Process for the preparation of the benzoic acid salt according to claim 1 , comprising dissolving methyl(2R,3R)-2-{3-[amino(imino)methyl]benzyl}-3-{[4-(1-oxidopyridin-4-yl)benzoyl]amino}butanoate in aqueous or aqueous-alcohol solution and adding benzoic acid or sodium benzoate.
7. A pharmaceutical composition comprising a benzoic acid salt of methyl(2R,3R)-2-{3-[amino(imino)methyl]benzyl}-3-{[4-(1-oxidopyridin-4-yl)benzoyl]amino}butanoate as claimed in claim 1 and a pharmaceutically acceptable carrier or excipient.
8. A method of treating acute myocardial infarction, non-ST elevation myocardial infarction, unstable angina, thromboembolism, acute vessel closure associated with thrombolytic therapy, percutaneous transluminal coronary angioplasty, transient ischemic attacks, stroke, intermittent claudication, and restenosis in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of the pharmaceutical composition of claim 7 .